title: Analysis Suggests Wider Use for PARP Inhibitors.
abstract: Researchers have developed a new tool, HRDetect, to pinpoint tumors that displayBRCAdeficiency but don't harborBRCA1/2mutations. Evaluating their method in breast, ovarian, and pancreatic cancers, they identified patients whose tumors were potentially vulnerable to PARP inhibition but who didn't carry these mutations.